TheraBionic

Executive Summary

TheraBionic is a Germany-based medical device company focused on developing a non-invasive, home-use treatment for cancer using low-level radiofrequency electromagnetic fields (also known as tumor-treating fields). Its lead product, the TheraBionic E100, received FDA Humanitarian Device Exemption (HDE) approval in 2021 for the treatment of unresectable hepatocellular carcinoma (liver cancer) in patients with poor prognosis. The device is designed to be self-administered by patients, offering a novel, well-tolerated approach with minimal side effects compared to traditional therapies. The company aims to address a significant unmet need in liver cancer, where treatment options are limited for advanced-stage patients. While the HDE approval restricts commercial use to a smaller patient population, TheraBionic is actively pursuing clinical trials to expand indications and gather data for broader approval, including potential CE marking in Europe. With a strong IP portfolio and growing awareness of non-invasive cancer treatments, TheraBionic represents an innovative player in the oncology medical device space, albeit with commercialization challenges typical of small private firms. The company's future depends on securing funding for larger trials, regulatory expansion, and adoption by clinicians.

Upcoming Catalysts (preview)

• Q4 2026Pivotal trial results for expanded HCC indication (post-HDE)45% success
• Q2 2027CE marking approval for European commercialization35% success
• Q3 2026Strategic partnership or licensing deal for US distribution50% success